Your survival rate for multiple myeloma is likely higher in earlier stages. Younger people often have better outcomes due to their resilience to intensive treatments. Advances in treatment have ...

Advancements in chemotherapy and immunotherapy have improved multiple myeloma survival rates, with 5-year relative survival increasing from 37.7% to 60.3% between 2000-2004 and 2015-2019. Treatment ...

Multiple myeloma is the second most common blood cancer in the United States. Thirty to 50 percent of multiple myeloma patients have extra copies of the gene that encodes the enzyme ADAR1. Using a ...

(RTTNews) - Johnson & Johnson (JNJ) shared new findings at the 2025 ASCO Annual Meeting from two Phase 3 studies, PERSEUS and CEPHEUS, highlighting the long-term benefits of a DARZALEX FASPRO ...

Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies in improving outcomes, particularly in regions with limited access to ...

SAN DIEGO -- A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed or refractory multiple myeloma should smooth the way for the ...

Staging is when a system is used to identify and describe how far a cancer has spread in your body. Knowing the stage of your multiple myeloma helps your physicians predict which treatments are most ...

Success is no longer just about prolonging survival, but about enabling patients to live well after cancer, with fewer ...

A Japanese government survey shows the five-year survival rates for patients aged 15 or older with pancreatic cancer, ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...